Drugs Made In America Acquisition Corp.
DMAA
$10.27
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -60.14% | 18.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -60.14% | 18.22% | |||
| Operating Income | 60.14% | -18.22% | |||
| Income Before Tax | 82.43% | 548.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 82.43% | 548.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 82.43% | 548.20% | |||
| EBIT | 60.14% | -18.22% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 34.98% | 254.74% | |||
| Normalized Basic EPS | 35.13% | 254.90% | |||
| EPS Diluted | 38.82% | 250.46% | |||
| Normalized Diluted EPS | 39.09% | 250.49% | |||
| Average Basic Shares Outstanding | 35.20% | 189.22% | |||
| Average Diluted Shares Outstanding | 31.40% | 197.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||